United Therapeutics Q3 Revenue Rises 4% as Net Income Falls 24%

Diluted earnings per share declined 20% to $5.71, while research and development expense more than doubled to $279.2 million.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.